Article

CIBA Vision to rebrand silicone hydrogel contact lenses

CIBA Vision has announced that Air Optix will be the global brand name for new products and product improvements to CIBA Vision's silicone hydrogel contact lenses in all markets worldwide.

Duluth, GA-CIBA Vision has announced that Air Optix will be the global brand name for new products and product improvements to CIBA Vision's silicone hydrogel contact lenses in all markets worldwide.

According to the company, having one global brand name will allow CIBA Vision to simplify its business operations and enhance customer satisfaction. It also will allow improved speed to market with future product innovations.

This spring will see the U.S. launch of its silicone hydrogel contact lens (Air Optix for Astigmatism). The lens has an 8 | 4 lens design that features a wide optic zone for optimal visual acuity and helps ensure that the lens fitting characteristics and axis orientation are consistent from patient to patient.

The lenses are made of lotrafilcon B and have a Dk/t of 108 @ –3.00 D. Launch parameters are from plano to –6.00 D in 0.25-D steps, with cylinder powers of –0.75 and –1.25 D and axes around-the-clock in 10° steps. They have a diameter of 14.5 mm, a base curve of 8.7 mm, and feature a blue handling tint. The lenses are approved for daily wear, up to 6 nights of extended wear, and are recommended for monthly replacement.

Including a recommended monthly modality for Air Optix products helps encourage higher patient compliance. Research provided by the company shows 56% patient compliance for wearing monthly lenses, an increase of more than twice the compliance rate of 1- to 2-week lenses. As few as 26% of patients wearing 1- to 2-week disposable-type contact lenses are compliant with the recommended replacement schedule.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.